Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.28 (
chloramphenicol acetyltransferase
)
5,100
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interferon-gamma (IFN-gamma) regulates a variety of immunoregulatory functions through the induction of a specific set of IFN-gamma response genes. This includes the invariant chain associated with the major histocompatibility complex class II molecules. To investigate the mechanism involved in the invariant chain (In) response to IFN-gamma we constructed
chloramphenicol acetyltransferase
(
CAT
) hybrid genes in which the
CAT
gene is under the control of the In promoter. The glioblastoma cell line, U-373 MG, transfected with a
CAT
construct having the In promoter sequence -790 to +1 bp showed over 3-fold increased
CAT
activity when treated with IFN-gamma indicating that this region confers IFN-gamma responsiveness to the
CAT
gene. The IFN-gamma response element in the promoter was further sublocalized to the region -120 to -61 base pairs (bp). This region contains homology to the interferon-stimulated response elements identified in other IFN responsive genes. By gel shift analyses, an IFN-gamma-induced sequence-specific DNA-binding factor was identified. This induced complex binds to an oligonucleotide corresponding to -107 to -79 bp of the In promoter. Mutations of this binding site at -94 and -92 bp drastically decreased binding of the constitutive and IFN-gamma-induced complexes. This IFN-gamma induced factor also binds to an oligonucleotide corresponding to -91 to -62 bp of the
interferon-beta
(
IFN-beta
) gene promoter, a region necessary for the induction of the
IFN-beta
gene by virus and double-stranded RNA. This binding specificity is characteristic of a family of DNA binding factors that bind both the interferon-stimulated response elements and the
IFN-beta
gene promoter.
...
PMID:Interferon-gamma-inducible regulation of the human invariant chain gene. 189 64
Matrix metalloproteinases are secreted enzymes important in inflammation and tumor invasion. Earlier, we demonstrated that in normal human FS-4 fibroblasts, collagenase and stromelysin mRNA levels are increased not only after treatment with known matrix metalloproteinase inducers such as tumor necrosis factor (TNF), interleukin-1, and 12-O-tetradecanoylphorbol-13-acetate, but also with
interferon-beta
(
IFN-beta
). In this study, we compared the regulation of these matrix metalloproteinase genes by TNF and
IFN-beta
. We show that both TNF and
IFN-beta
increase steady-state levels of collagenase and stromelysin mRNAs with similar slow kinetics. The glucocorticoid dexamethasone blocked matrix metalloproteinase induction by both cytokines. The protein synthesis inhibitor cycloheximide inhibited collagenase mRNA induction by TNF or
IFN-beta
, suggesting that induction by both agents is indirect. Consistent with these observations, both TNF and
IFN-beta
increased c-fos and c-jun mRNA levels. Furthermore, treatment with TNF or
IFN-beta
increased the transcriptional activity of activator protein-1-responsive
chloramphenicol acetyltransferase
reporter gene constructs, including a native collagenase promoter-driven
chloramphenicol acetyltransferase
construct. These findings show that regulation of matrix metalloproteinase gene expression by both TNF and
IFN-beta
involves the transcription factor activator protein-1 and demonstrate a novel indirect mechanism of type I IFN-induced gene expression.
...
PMID:Interferon-beta induces metalloproteinase mRNA expression in human fibroblasts. Role of activator protein-1. 806 4
Heterologous expression of cloned receptor subtypes for screening programs has become a real necessity for a modern pharmaceutical company. As the expression levels obtained so far are often low or unstable, we addressed this problem by using an inducible promoter system, i.e. the interferon-inducible mouse Mxl promoter. Using the gene coding for
chloramphenicol acetyltransferase
(
CAT
) as a reporter gene, we tested the inducibility of this promoter in the murine cell line L929. We found that background expression was low and that a distinct interferon-induced expression could be obtained.
CAT
expression reached its maximum at approximately 15 ng
CAT
/mg protein after induction for 24 hr with 1000 U/ml murine
interferon-beta
; the induction ratio was 150-fold. Next, L929 cells were transfected with four different human serotonin (5HT) receptor cDNAs (5HT1A, 5HT2A, 5HT1D beta and 5HT1E) under the control of the same Mxl promoter fragment. Also in this case well-regulated serotonin receptor-expressing clones were isolated. Bmax values varied from 3100 fmol/mg protein for the 5HT2A receptor, 3300 fmol/mg protein for the 5HT1D beta receptor, 9800 fmol/mg protein for the 5HT1E receptor, and even up to 10,400 fmol/mg protein for the 5HT1A receptor. Furthermore, the expression levels were shown to remain stable during serial propagation for at least one year, demonstrating the usefulness of this expression system. In fact, the 5HT1D beta receptor-expressing cells were used in the characterization of a new antimigraine agent, viz. alniditan.
...
PMID:Stable, high-level expression of human serotonin receptors in L929 cells using an inducible expression system. 960 17